Emcure Pharmaceuticals

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Emcure Pharmaceuticals Limited
MNC (JVs and subsidiaries)
Industry Pharmaceutical
Founded 1983
Headquarters Hinjwadi, Pune, India
Key people

Satish Mehta

[1] CEO
Products tablets, capsules, softgels, injectables, Lyophilized sterile parenterals, Onco products
₹1,500+ crore (US$220;Million)
Number of employees
9000+
Website www.emcure.co.in

Emcure Pharmaceuticals headquartered at Pune in West India is an Indian pharmaceutical company. The company's products include tablets, capsules (both softgel capsules and hard-gel capsules), and injectables.

Indian plants[edit]

  • Solid Dosage facility at Hinjawadi - In 2006, Emcure received US FDA approval for its solid dosages facility at Hinjwadi, Pune. The plant manufactures solid oral formulations for the international regulated markets.
  • Small volume parenteral facility at Hinjawadi - US FDA, UK MHRA approved. Has lyophilization and pfs capability
  • Oncology injectable facility at Hinjawadi
  • Solid Orals facilities at Jammu and Bhosari
  • API facility at Kurkumbh- USFDA approved
  • Biotech facility at Hinjawadi
  • R&D center and upcoming plant at Ahmedabad

US plant[edit]

USA - The company has a manufacturing facility and R&D center at East Brunswick, New Jersey, USA.

Capital markets[edit]

Emcure is planning to raise money through an initial public offering for some time now [2] In 2014, Blackstone sold its stake in Emcure to Bain Capital [3]

Recalls[edit]

There have been cases of recalls announced by Pharma majors like Pfizer & Teva after having manufactured their products with their partner Emcure. In 2010, Pfizer had to recall three batches of an anti-bacterial product from the US market due to presence of Penicillium Chrysogenum & E coli in some samples.[4] Teva recalled several batches of two products due to white tablets showing discoloration in 2011.[5]

AIDS Initiative[edit]

Emcure voices its concerns on HIV/AIDS through its "Let's fight AIDS together" initiative and supplies Antiretroviral drugs to Africa, Asia Pacific and CIS. As a part of its corporate social responsibility it supports 'Taal', a pharmacy for HIV/AIDS patients run by HIV/AIDS patients.

Emcure has license agreements with Bristol-Myers Squibb for Atazanavir [6] and Gilead Sciences for Tenofovir [7] as part of their Global Access Programs.

Anticancer portfolio[edit]

Roche has signed a deal with Emcure for manufacturing its blockbuster anticancer drugs Herceptin and Mabthera in India.[8] Under this programme the cancer drugs shall be made available to the developing world at an affordable 'cut-price' version.[9] The monthly doses priced at around $300000 are expected to be slashed significantly for wider access to cancer therapy.

Group Companies[edit]

References[edit]

External links[edit]